The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases
Copyright © 2012 Wiley Periodicals, Inc..
The interleukin 28B (IL-28B) rs12979860 C/T polymorphism is a predictor of spontaneous and treatment-induced hepatitis C virus (HCV) clearance. The C/C genotype is associated with higher serum cholesterol, predictor of a favorable outcome in chronic hepatitis C. Whether IL-28B polymorphism and serum cholesterol play a role in modulating the history of mild hepatitis C is unknown. To clarify this issue, 93 untreated patients infected with HCV with normal or near-normal transaminases and an initial Ishak staging score ≤1 were investigated retrospectively in the longitudinal study (median histological follow-up of 10 years). An additional confirmatory cohort of 143 patients with chronic HCV infection and abnormal levels of transaminases was evaluated in the cross-sectional study. In the longitudinal study, at the end of follow-up, Ishak staging scores progressed more frequently among carriers of a T/* allele who had a baseline serum cholesterol ≤175 mg/dl than in remaining patients: 6/36 (change ≤0), 15/45 (change 1-2), 6/12 (change ≥3), improvement chi-square P < 0.02, OR 3.1, 95% C.I. 1.3-7.7. In the cross-sectional study, the frequency of patients carrying the T/T genotype or serum cholesterol values ≤175 mg/dl increased starting from those with a staging score ≤2 (36/76, 47.4%), to those with a staging score of 3-4 (26/41, 63.4%) and to those with a staging score of 5-6 (20/26, 76.9%, P < 0.01 for linear trend). In conclusion, the interaction between IL-28B rs12979860 T/T genotype and low serum cholesterol concentration is an independent predictor of a worse disease course among patients infected with HCV with normal or near-normal transaminases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Journal of medical virology - 84(2012), 5 vom: 20. Mai, Seite 747-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fabris, Carlo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9008-11-1 |
|---|
| Anmerkungen: |
Date Completed 11.07.2012 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.23259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM216328675 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM216328675 | ||
| 003 | DE-627 | ||
| 005 | 20231227124529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.23259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1222.xml |
| 035 | |a (DE-627)NLM216328675 | ||
| 035 | |a (NLM)22431022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fabris, Carlo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2012 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2012 Wiley Periodicals, Inc. | ||
| 520 | |a The interleukin 28B (IL-28B) rs12979860 C/T polymorphism is a predictor of spontaneous and treatment-induced hepatitis C virus (HCV) clearance. The C/C genotype is associated with higher serum cholesterol, predictor of a favorable outcome in chronic hepatitis C. Whether IL-28B polymorphism and serum cholesterol play a role in modulating the history of mild hepatitis C is unknown. To clarify this issue, 93 untreated patients infected with HCV with normal or near-normal transaminases and an initial Ishak staging score ≤1 were investigated retrospectively in the longitudinal study (median histological follow-up of 10 years). An additional confirmatory cohort of 143 patients with chronic HCV infection and abnormal levels of transaminases was evaluated in the cross-sectional study. In the longitudinal study, at the end of follow-up, Ishak staging scores progressed more frequently among carriers of a T/* allele who had a baseline serum cholesterol ≤175 mg/dl than in remaining patients: 6/36 (change ≤0), 15/45 (change 1-2), 6/12 (change ≥3), improvement chi-square P < 0.02, OR 3.1, 95% C.I. 1.3-7.7. In the cross-sectional study, the frequency of patients carrying the T/T genotype or serum cholesterol values ≤175 mg/dl increased starting from those with a staging score ≤2 (36/76, 47.4%), to those with a staging score of 3-4 (26/41, 63.4%) and to those with a staging score of 5-6 (20/26, 76.9%, P < 0.01 for linear trend). In conclusion, the interaction between IL-28B rs12979860 T/T genotype and low serum cholesterol concentration is an independent predictor of a worse disease course among patients infected with HCV with normal or near-normal transaminases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a interferon-lambda, human |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Transaminases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.- |2 NLM | |
| 700 | 1 | |a Falleti, Edmondo |e verfasserin |4 aut | |
| 700 | 1 | |a Cussigh, Annarosa |e verfasserin |4 aut | |
| 700 | 1 | |a Bitetto, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Fontanini, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Colletta, Cosimo |e verfasserin |4 aut | |
| 700 | 1 | |a Vandelli, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Cmet, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Ceriani, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Smirne, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Toniutto, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Pirisi, Mario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 84(2012), 5 vom: 20. Mai, Seite 747-55 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2012 |g number:5 |g day:20 |g month:05 |g pages:747-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.23259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2012 |e 5 |b 20 |c 05 |h 747-55 | ||